LivaNova to Divest Cardiac Rhythm Management Business to Microport Scientific

LivaNova PLC announced that it has entered into a definitive Stock and Asset Purchase Agreement (“Purchase Agreement”) to divest its Cardiac Rhythm Management business franchise to MicroPort Scientific Corporation. LivaNova and MicroPort executed and delivered the Purchase Agreement, pursuant to the terms of a binding Letter of Intent, previously announced on November 20, 2017.
 
Today’s announcement follows the successful completion of works council information and consultation requirements in France. The proposed transaction is subject to customary regulatory and other closing conditions. The transaction is expected to close in the second quarter of 2018.